Triple Negative Breast Cancer's Progression and Relapse Pinned to a Gene

Released: 24-Mar-2014 11:00 AM EDT
Source Newsroom: Houston Methodist
Contact Information

Available for logged-in reporters only

Citations Nature April 3 (advanced online publication)

Newswise — HOUSTON -- (March 24, 2014) -- Scientists from Houston Methodist and Weill Cornell Medical College have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, which can be particularly deadly, with few treatment options. Their research, published in the April 3 Nature (online today), suggests that targeting the gene may be a new approach to treat the disease.

"We are really beginning to understand what initiates the cancer and why cancer cells evade treatment," said coauthor and Houston Methodist Cancer Center Director Jenny Chang, M.D. "Our group learned this pathway was activated in about two-thirds of patients with this type of breast cancer, and we believe we may be able to treat the disease by manipulating elements of the pathway."

About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses. Patients who relapse typically do so within one to three years of being treated.

Senior author Laurie H. Glimcher, M.D., the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, wanted to know whether the gene -- already understood from her prior work to be a critical regulator of immune and metabolic functions -- was important to cancer's ability to adapt and thrive in the oxygen- and nutrient-deprived environments inside of tumors. Using cells taken from patients' tumors and transplanted into mice, Glimcher's team found that the gene, XBP1, is especially active in TNBC, particularly in the progression of malignant cells and their resurgence after treatment.

"Patients with the triple negative form of breast cancer are those who most desperately need new approaches to treat their disease," said Glimcher, who is also a professor of medicine at Weill Cornell. "This pathway was activated in about two-thirds of patients with this type of breast cancer. Now that we better understand how this gene helps tumors proliferate and then return after a patient's initial treatment, we believe we can develop more effective therapies to shrink their growth and delay relapse."

The group, which included investigators from nine institutions, examined several types of breast cancer cell lines. They found that XBP1 was particularly active in basal-like breast cancer cells cultivated in the lab and in TNBC cells from patients. When they suppressed the activity of the gene in laboratory cell cultures and animal models, however, the researchers were able to dramatically reduce the size of tumors and the likelihood of relapse, especially when these approaches were used in conjunction with the chemotherapy drugs doxorubicin or paclitaxel. The finding suggests that XBP1 controls behaviors associated with tumor-initiating cells that have been implicated as the originators of tumors in a number of cancers, including that of the breast, supporting the hypothesis that combination therapy could be an effective treatment for TNBC.

The scientists also found that interactions between XBP1 and another transcriptional regulator, HIF1-alpha, spurs the cancer-driving proteins. Silencing XBP1 in the TNBC cell lines reduced the tumor cells' growth and other behaviors typical of metastasis.

"This starts to demonstrate how cancer cells co-opt the endoplasmic reticulum stress response pathway to allow tumors to grow and survive when they are deprived of nutrients and oxygen," said lead author Xi Chen, Ph.D., a postdoctoral associate at Weill Cornell, referring to the process by which healthy cells maintain their function. "It shows the interaction between two critical pathways to make the cells better able to deal with a hostile microenvironment, and in that way offers new strategies to target triple negative breast cancer."

Scientists still need to study how those strategies would help women with the disease.

"Obviously we need to know now whether what our group saw in models is what we'll see in patients," Chang said. "We are very excited about the prospect of moving this research forward as soon as possible for the benefit of patients."

###

Also contributing to the Nature report were Junhua Mai, Haifa Shen, Melissa D. Landis, and Mauro Ferrari (Houston Methodist Hospital), Minkyung Song, Chen Tan, Stanley Adoro, and Sandra J. Shin (Weill Cornell Medical College), Dimitrios Iliopoulos and Maria Hatziapostolou (University of California, Los Angeles), Qing Zhang (University of North Carolina at Chapel Hill), Qianzi Tang (Tongji University and Sichuan Agricultural University, China), Matthew B. Greenblatt (Brigham and Women's Hospital), Elgene Lim, Min Ni, Yiwen Chen, X. Shirley Liu, and Myles Brown (Dana-Farber Cancer Institute and Harvard Medical School), Wai Leong Tam (Whitehead Institute for Biomedical Research), Dorothy Z. Hu (Massachusetts General Hospital), Bella Hu (Children's Hospital Boston). The study was funded by the National Institutes of Health (CA112663 and AI32412) and the Leukemia and Lymphoma Society.

To speak with Jenny Chang, M.D., please contact David Bricker, Houston Methodist, at 832-667-5811 or dmbricker@houstonmethodist.org. To speak with Laurie Glimcher or Xi Chen, Ph.D., please contact Jennifer Gundersen at 646-317-7402 or jeg2034@med.cornell.edu.


Comment/Share